Sai Parenteral acquires stake in Australian pharma firm for ₹125 crore

Sai Parenteral Acquires 74.6% Stake in Noumed Pharmaceuticals for ₹125 Crore

Sai Parenteral, an IPO-bound pharmaceutical formulations company, has made a significant move by acquiring a 74.6% stake in Adelaide-based Noumed Pharmaceuticals for ₹125 crore.

About Noumed Pharmaceuticals

• Noumed Pharmaceuticals is a supplier of private label over-the-counter (OTC) products to pharmacy chains across Australia and New Zealand.
• The company has generated AUD 60 million in revenue.
• Noumed is in the process of establishing a AUD 53 million manufacturing facility in Adelaide, which is expected to begin commercial operations by the fourth quarter of 2026.

Key Highlights of the Acquisition

• Noumed offers a portfolio of over 451 product dossiers, providing substantial breadth across therapeutic categories.
• The acquisition aligns with Sai Parenteral's aspirations to become a global, innovation-led formulations and CDMO platform.

Quote from Managing Directors

“This partnership enhances our entry into semi-regulated and regulated markets with a wider, more competitive product portfolio,” said Anil KK, Managing Director at Sai Parenterals.

“Having worked with Sai Parenteral's for a considerable time, we are confident that together we can accelerate our product pipeline, benefit from Sai's manufacturing capabilities and meet growing demand in the Australian, New Zealand and global markets,” said Mark Thulborne, Managing Director at Noumed Pharmaceuticals.

Related News

• Sai Parenteral files DRHP with SEBI for initial public offering.
• The IPO will comprise a fresh issue of up to ₹285 crore and an offer for sale of up to 35 lakh shares by existing shareholders.